Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference
09/08/2022 - 07:00 AM
NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company’s website at https://investors.renalytix.com beginning at 7:00 a.m. Eastern Time on September 12, 2022.
About Renalytix Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com .
For further information, please contact:
Renalytix plc www.renalytix.com James McCullough, CEO Via Walbrook PR Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600 Alex Price / Nicholas Moore Investec Bank plc (Joint Broker) Tel: 020 7597 4000 Gary Clarence / Daniel Adams Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com Paul McManus / Lianne Applegarth / Alice Woodings Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 CapComm Partners Tel: 415-389-6400 or investors@renalytix.com Peter DeNardo
RNLX Rankings
#4481 Ranked by Stock Gains
RNLX Stock Data
Industry
Diagnostic Imaging Centers
Sector
Health Care and Social Assistance
Tags
Technology Services, Packaged Software, Health Care and Social Assistance, Diagnostic Imaging Centers
Country
United Kingdom
City
Penarth
About RNLX
renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev